View in EDS

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.
Authors: Manzi S; Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania., Bruce IN; Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom.; Centre for Public Health, Faculty of Medicine, Health, and Life Sciences, Queen's University Belfast, Belfast, United Kingdom., Morand EF; Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia., Furie R; Division of Rheumatology, Northwell, Great Neck, New York., Tanaka Y; Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan., Kalunian KC; Lupus Center of Excellence, Division of Rheumatology, Autoimmunity, and Inflammation, University of California, San Diego School of Medicine, La Jolla, California., Askanase A; Division of Rheumatology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York., Puzio P; BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland., Khan E; BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom., Wissmar J; BioPharmaceuticals R&D, Late-Stage Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden., Song M; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, Massachusetts., Lindholm C; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden.
Corporate Authors: TULIP‐SC investigators
Source: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2026 Jun; Vol. 78 (6), pp. 1258-1267. Date of Electronic Publication: 2026 Feb 17.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41466456
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Manzi+S%22">Manzi S</searchLink>; Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Bruce+IN%22">Bruce IN</searchLink>; Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom.; Centre for Public Health, Faculty of Medicine, Health, and Life Sciences, Queen's University Belfast, Belfast, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Morand+EF%22">Morand EF</searchLink>; Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Furie+R%22">Furie R</searchLink>; Division of Rheumatology, Northwell, Great Neck, New York.<br /><searchLink fieldCode="AU" term="%22Tanaka+Y%22">Tanaka Y</searchLink>; Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.<br /><searchLink fieldCode="AU" term="%22Kalunian+KC%22">Kalunian KC</searchLink>; Lupus Center of Excellence, Division of Rheumatology, Autoimmunity, and Inflammation, University of California, San Diego School of Medicine, La Jolla, California.<br /><searchLink fieldCode="AU" term="%22Askanase+A%22">Askanase A</searchLink>; Division of Rheumatology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York.<br /><searchLink fieldCode="AU" term="%22Puzio+P%22">Puzio P</searchLink>; BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland.<br /><searchLink fieldCode="AU" term="%22Khan+E%22">Khan E</searchLink>; BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wissmar+J%22">Wissmar J</searchLink>; BioPharmaceuticals R&D, Late-Stage Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Song+M%22">Song M</searchLink>; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Lindholm+C%22">Lindholm C</searchLink>; BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22TULIP‐SC+investigators%22">TULIP‐SC investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101623795%22">Arthritis & rheumatology (Hoboken, N.J.)</searchLink> [Arthritis Rheumatol] 2026 Jun; Vol. 78 (6), pp. 1258-1267. <i>Date of Electronic Publication: </i>2026 Feb 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101623795 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2326-5205 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223265191%22">23265191 </searchLink><i>NLM ISO Abbreviation: </i>Arthritis Rheumatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41466456
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/art.70041
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1258
    Titles:
      – TitleFull: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Manzi S
      – PersonEntity:
          Name:
            NameFull: Bruce IN
      – PersonEntity:
          Name:
            NameFull: Morand EF
      – PersonEntity:
          Name:
            NameFull: Furie R
      – PersonEntity:
          Name:
            NameFull: Tanaka Y
      – PersonEntity:
          Name:
            NameFull: Kalunian KC
      – PersonEntity:
          Name:
            NameFull: Askanase A
      – PersonEntity:
          Name:
            NameFull: Puzio P
      – PersonEntity:
          Name:
            NameFull: Khan E
      – PersonEntity:
          Name:
            NameFull: Wissmar J
      – PersonEntity:
          Name:
            NameFull: Song M
      – PersonEntity:
          Name:
            NameFull: Lindholm C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2326-5205
          Numbering:
            – Type: volume
              Value: 78
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Arthritis & rheumatology (Hoboken, N.J.)
              Type: main
ResultId 1